Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIS: Injectable Cabotegravir PrEP in South African Pharmacies
NCT06138600Phase 3Active, not recruiting
- Sponsor
- University of the Witwatersrand
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by University of the Witwatersrand. Started Nov 2023; status: active, not recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06138600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138600.